+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Osteoporosis Drugs Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis

  • PDF Icon

    Report

  • 130 Pages
  • February 2022
  • Region: Global
  • Renub Research
  • ID: 5546206
Global Osteoporosis Drugs Market is projected to reach US$ 16.43 Billion in 2027. Osteoporosis is a chronic and life-threatening disorder in which the microstructure of bones is altered due to a reduction in bone mass and bone density. Besides, this condition leads to increased bone fragility and the threat of bone cracks and fractures. Remarkably, as there is no cure for osteoporosis, FDA has approved drugs to prevent, slow, or stop osteoporosis progress. Further, taking prescribed osteoporosis drugs, along with other healthy lifestyle behaviors such as getting enough calcium, vitamin D, and regular exercise, helps in reducing the risk of broken bones (also called fractures) due to osteoporosis globally.



Worldwide Osteoporosis Drugs Market reached US$ 12.01 Billion in 2021


Remarkably, as there is no distinct substitute available to treat osteoporosis (such as surgery), the drugs industry is an inevitable part of osteoporosis treatment worldwide. Globally, Osteoporosis Drugs Market is primarily driven by a significant rise in the prevalence of osteoporosis disorder. Besides, an unprecedented increase in the prevalence of osteoporosis results in the high demand for drugs to prevent and treat osteoporosis, thus widening the growth potential over the forecasted years. Moreover, the senior population globally possessing high susceptibility for osteoporosis is further presumed to boost the high demand for Osteoporosis Drugs.

The Classes of Drugs Have Been Successful and is expected to Remain Successful over the Forecast Period:


Drug Class's currently marketed products in the osteoporosis space are all antiresorptive therapies. These include bisphosphonates, selective estrogen inhibitors modulator (serm), parathyroid hormone therapy, calcitonin, and rank ligand inhibitors. As per our analysis, the classes of drugs have been successful since the mid-1990s, and we expect them to remain successful over the forecast period.

Nevertheless, there has been a significant paradigm shift in development strategies for late- and mid-stage osteoporosis drug development. Pharmaceutical companies have pivoted their focus to devising anabolic drugs rather than antiresorptive therapies. Anabolic drugs operate against osteoporosis advancement in a manner opposite that of the antiresorptive by stimulating the formation of new bone instead of the retardation of bone resorption.

Injectable Route of Administration is Accelerating the Growth in the Market:


The osteoporosis drug market is categorized into oral and injectable by route of administration. The oral route of administration leads the market owing to the increase in the adoption of oral drugs. Along with this, the rise in consumption of oral medication is further affecting a more significant production, which is positively influencing the market's growth over the years. In contrast, the injectable route of the administration segment is anticipated to accelerate its growth during the forecast period. Moreover, the launch of some new biosimilar is more convenient for consumption without any risk in osteoporosis treatment.

By Types, Branded and Generic Osteoporosis Drugs Controls the Global Osteoporosis Drugs Market:


In our report, we have covered branded and generic osteoporosis drugs by type. While the branded osteoporosis drug will undoubtedly maintain a stronghold in the industrial paradigm, their rank as the gold standard will be increasingly contested by the generic osteoporosis drugs entering the market. Hence, we anticipate that the demand for generic osteoporosis drugs market will undergo a fundamental shift with their increasing preference by consumers in the market. In terms of market trends, we expect consumers to be inclined to generic osteoporosis drugs, which will be available abundantly during the forecast period.

Regional Insights: North America accounts for a Lion’s Share


North America accounts for a predominant share in the overall market. Moreover, several collaborative efforts undertaken by major companies to enhance their R&D capabilities and ensure high medical standards are anticipated to propel the demand for osteoporosis drugs across the American region. Moreover, the majority share can also be attributed to the high disease burden in North America.

Contrarily, the Asia Pacific market is expected to grow at a lucrative rate over the forecasted years. As per our estimates, the high growth registered by the Asia Pacific is believed to be a consequence of consistent R&D investments deployed by the prominent players and their efforts to commercialize branded and generic therapeutics at a relatively low price. According to the publisher, Global Osteoporosis Drugs Industry is registering a CAGR of 5.4% during 2021-2027.

Key Players Insights of Osteoporosis Drugs Industry:


Key leaders in the Global Osteoporosis Drugs Industry include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Novartis International AG, Merck & Co. Inc., and Amgen Inc. These companies have many blockbuster drugs in their portfolio for Osteoporosis. Moreover, the market leaders during the forecast period with their pipeline products will reshape the osteoporosis drugs market once launched. Remarkably, the key players will face stiff competition amongst the players.

Effect of COVID-19 on Global Osteoporosis Drugs Market:


In 2020, the COVID-19 pandemic reduced the demand for osteoporosis drugs for a brief period owing to a reduction in reported cases of ailments. Further, post-recovery from the COVID-19, the market is expected to witness a surge in demand with growing relaxations in people's movements. As per our analysis, treatments with osteoporosis drugs reduce the rate of COVID-19 infection. Thus, we conclude that Osteoporosis Drugs Market is likely to witness a positive impact of COVID-19.

This latest research report “Osteoporosis Drugs Market, Global Forecast by Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, Others), Route of Administration (Oral, Injectable, Others), Type (Branded, Generic), Region (North America, Asia Pacific, Europe, Middle East and Africa, South America), Companies (Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Novartis International AG, Merck & Co. Inc., and Amgen Inc)” provides a detailed analysis of Osteoporosis Drugs Industry.

Drug Class - Market has been covered from 6 viewpoints:


  • Bisphosphonates
  • Selective Estrogen Inhibitors Modulator (SERM)
  • Parathyroid Hormone Therapy
  • Calcitonin
  • Rank Ligand Inhibitors
  • Others

Route of Administration - Drugs Market has been covered from 3 viewpoints:


  • Oral
  • Injectable
  • Others

Type - Market has been covered from 2 viewpoints:


  • Branded
  • Generic

Region - Market has been covered from 5 viewpoints:


  • North America
  • Asia Pacific
  • Europe
  • Middle East and Africa
  • South America

Company Insights:


  • Overview
  • Recent Development
  • Financial Insight

Company Analysis:


  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.
Frequently Asked Questions about the Global Osteoporosis Drugs Market

What is the estimated value of the Global Osteoporosis Drugs Market?

The Global Osteoporosis Drugs Market was estimated to be valued at $12.0 Billion in 2021.

What is the growth rate of the Global Osteoporosis Drugs Market?

The growth rate of the Global Osteoporosis Drugs Market is 5.4%, with an estimated value of $16.4 Billion by 2027.

What is the forecasted size of the Global Osteoporosis Drugs Market?

The Global Osteoporosis Drugs Market is estimated to be worth $16.4 Billion by 2027.

Who are the key companies in the Global Osteoporosis Drugs Market?

Key companies in the Global Osteoporosis Drugs Market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann, La Roche, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Novartis International AG and Amgen Inc..

Table of Contents

1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Osteoporosis Drugs Market
6. Market Share - Global Osteoporosis Drugs Market
6.1 By Drug Class
6.2 By Route of Administration
6.3 By Type
6.4 By Region
7. Drug Class - Global Osteoporosis Drugs Market
7.1 Bisphosphonates
7.2 Selective Estrogen Inhibitors Modulator (SERM)
7.3 Parathyroid Hormone Therapy
7.4 Calcitonin
7.5 Rank Ligand Inhibitors
7.6 Others
8. Route of Administration - Global Osteoporosis Drugs Market
8.1 Oral
8.2 Injectable
8.3 Others
9. Type - Global Osteoporosis Drugs Market
9.1 Branded
9.2 Generic
10. Region - Lithium-Ion Battery Market
10.1 North America
10.2 Asia Pacific
10.3 Europe
10.4 Middle East and Africa
10.5 South America
11. Porters Five Forces
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12. Company Analysis
12.1 Eli Lilly and Company
12.1.1 Overview
12.1.2 Recent Development
12.1.3 Financial Insight
12.2 Pfizer Inc.
12.2.1 Overview
12.2.2 Recent Developmen
12.2.3 Financial Insight
12.3 F. Hoffmann-La Roch
12.3.1 Overview
12.3.2 Recent Development
12.3.3 Financial Insight
12.4 Teva Pharmaceutical Industries Ltd.
12.4.1 Overview
12.4.2 Recent Development
12.4.3 Financial Insight
12.5 GlaxoSmithKline plc.
12.5.1 Overview
12.5.2 Recent Development
12.5.3 Financial Insight
12.6 Novartis International AG
12.6.1 Overview
12.6.2 Recent Development
12.6.3 Financial Insight
12.7 Merck & Co. Inc.
12.7.1 Overview
12.7.2 Recent Development
12.7.3 Financial Insight
12.8 Amgen Inc.
12.8.1 Overview
12.8.2 Recent Development
12.8.3 Financial Insight
List of Figures
Figure 01: Global - Osteoporosis Drugs Market (Billion US$), 2018 - 2021
Figure 02: Global - Forecast for Osteoporosis Drugs Market (Billion US$), 2022 - 2027
Figure 03: Drug Class - Bisphosphonates Market (Billion US$), 2018 - 2021
Figure 04: Drug Class - Forecast for Bisphosphonates Market (Billion US$), 2022 - 2027
Figure 05: Drug Class - Selective Estrogen Inhibitors Modulator (SERM) Market (Million US$), 2018 - 2021
Figure 06: Drug Class - Forecast for Selective Estrogen Inhibitors Modulator (SERM) Market (Million US$), 2022 - 2027
Figure 07: Drug Class - Parathyroid Hormone Therapy Market (Billion US$), 2018 - 2021
Figure 08: Drug Class - Forecast for Parathyroid Hormone Therapy Market (Billion US$), 2022 - 2027
Figure 09: Drug Class - Calcitonin Market (Million US$), 2018 - 2021
Figure 10: Drug Class - Forecast for Calcitonin Market (Million US$), 2022 - 2027
Figure 11: Drug Class - Rank Ligand Inhibitors Market (Billion US$), 2018 - 2021
Figure 12: Drug Class - Forecast for Rank Ligand Inhibitors Market (Billion US$), 2022 - 2027
Figure 13: Drug Class - Others Market (Billion US$), 2018 - 2021
Figure 14: Drug Class - Forecast for Others Market (Billion US$), 2022 - 2027
Figure 15: Route of Administration - Oral Market (Billion US$), 2018 - 2021
Figure 16: Route of Administration - Forecast for Oral Market (Billion US$), 2022 - 2027
Figure 17: Route of Administration - Injectable Market (Billion US$), 2018 - 2021
Figure 18: Route of Administration - Forecast for Injectable Market (Billion US$), 2022 - 2027
Figure 19: Route of Administration - Others Market (Million US$), 2018 - 2021
Figure 20: Route of Administration - Forecast for Others Market (Million US$), 2022 - 2027
Figure 21: Type - Branded Market (Billion US$), 2018 - 2021
Figure 22: Type - Forecast for Branded Market (Billion US$), 2022 - 2027
Figure 23: Type - Generic Market (Billion US$), 2018 - 2021
Figure 24: Type - Forecast for Generic Market (Billion US$), 2022 - 2027
Figure 25: North America - Osteoporosis Drugs Market (Billion US$), 2018 - 2021
Figure 26: North America - Forecast for Osteoporosis Drugs Market (Billion US$), 2022 - 2027
Figure 27: Asia Pacific - Osteoporosis Drugs Market (Billion US$), 2018 - 2021
Figure 28: Asia Pacific - Forecast for Osteoporosis Drugs Market (Billion US$), 2022 - 2027
Figure 29: Europe - Osteoporosis Drugs Market (Billion US$), 2018 - 2021
Figure 30: Europe - Forecast for Osteoporosis Drugs Market (Billion US$), 2022 - 2027
Figure 31: Middle East and Africa - Osteoporosis Drugs Market (Million US$), 2018 - 2021
Figure 32: Middle East and Africa - Forecast for Osteoporosis Drugs Market (Million US$), 2022 - 2027
Figure 33: South America - Osteoporosis Drugs Market (Million US$), 2018 - 2021
Figure 34: South America - Forecast for Osteoporosis Drugs Market (Million US$), 2022 - 2027
Figure 35: Eli Lilly and Company - Global Revenue (Billion US$), 2018 - 2021
Figure 36: Eli Lilly and Company - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 37: Pfizer Inc. - Global Revenue (Billion US$), 2018 - 2021
Figure 38: Pfizer Inc. - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 39: F. Hoffmann-La Roche - Global Revenue (Billion US$), 2018 - 2021
Figure 40: F. Hoffmann-La Roche - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 41: Teva Pharmaceutical Industries Ltd. - Global Revenue (Billion US$), 2018 - 2021
Figure 42: Teva Pharmaceutical Industries Ltd. - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 43: GlaxoSmithKline plc. - Global Revenue (Billion US$), 2018 - 2021
Figure 44: GlaxoSmithKline plc. - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 45: Novartis International AG - Global Revenue (Billion US$), 2018 - 2021
Figure 46: Novartis International AG - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 47: Merck & Co. Inc. - Global Revenue (Billion US$), 2018 - 2021
Figure 48: Merck & Co. Inc. - Forecast for Global Revenue (Billion US$), 2022 - 2027
Figure 49: Amgen Inc. - Global Revenue (Billion US$), 2018 - 2021
Figure 50: Amgen Inc. - Forecast for Global Revenue (Billion US$), 2022 - 2027
List of Tables
Table 01: Global - Osteoporosis Drugs Market Share by Drug Class (Percent), 2018 - 2021
Table 02: Global - Forecast for Osteoporosis Drugs Market Share by Drug Class (Percent), 2022 - 2027
Table 03: Global - Osteoporosis Drugs Market Share by Route of Administration (Percent), 2018 - 2021
Table 04: Global - Forecast for Osteoporosis Drugs Market Share by Route of Administration (Percent), 2022 - 2027
Table 05: Global - Osteoporosis Drugs Market Share by Type (Percent), 2018 - 2021
Table 06: Global - Forecast for Osteoporosis Drugs Market Share by Type (Percent), 2022 - 2027
Table 07: Global - Osteoporosis Drugs Market Share by Region (Percent), 2018 - 2021
Table 08: Global - Forecast for Osteoporosis Drugs Market Share by Region (Percent), 2022 - 2027

Companies Mentioned

  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.

Methodology

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...